We investigated a patient who developed multiple sclerosis (MS) during treatment with the CTLA4-blocking antibody ipilimumab for metastatic melanoma. Initially he showed subclinical magnetic resonance imaging (MRI) changes (radiologically isolated syndrome). Two courses of ipilimumab were each followed by a clinical episode of MS, 1 of which was accompanied by a massive increase of MRI activity. Brain biopsy confirmed active, T-cell type MS. Quantitative next generation sequencing of T-cell receptor genes revealed distinct oligoclonal CD4 1 and CD8 1 Tcell repertoires in the primary melanoma and cerebrospinal fluid. Our results pinpoint the coinhibitory molecule CTLA4 as an immunological checkpoint and therapeutic target in MS. ANN NEUROL 2016;80:294-300 A n autoimmune pathogenesis of multiple sclerosis (MS) is supported by different indirect arguments, including the partial efficacy of immunomodulatory treatments, analogies with autoimmune animal models of central nervous system (CNS) inflammation, and converging evidence from genetics studies.
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We investigated a patient who developed multiple sclerosis (MS) during treatment with the CTLA4-blocking antibody ipilimumab for metastatic melanoma. Initially he showed subclinical magnetic resonance imaging (MRI) changes (radiologically isolated syndrome). Two courses of ipilimumab were each followed by a clinical episode of MS, 1 of which was accompanied by a massive increase of MRI activity. Brain biopsy confirmed active, T-cell type MS. Quantitative next generation sequencing of T-cell receptor genes revealed distinct oligoclonal CD4
1 and CD8 1 Tcell repertoires in the primary melanoma and cerebrospinal fluid. Our results pinpoint the coinhibitory molecule CTLA4 as an immunological checkpoint and therapeutic target in MS. ANN NEUROL 2016; 80:294-300 A n autoimmune pathogenesis of multiple sclerosis (MS) is supported by different indirect arguments, including the partial efficacy of immunomodulatory treatments, analogies with autoimmune animal models of central nervous system (CNS) inflammation, and converging evidence from genetics studies. [1] [2] [3] [4] Specifically, genome-wide association studies (GWAS) identified numerous risk variants implicated in the regulation, differentiation, or activation of T lymphocytes. 5, 6 The strongest genetic risk factor is HLA-DRB1*15:01, which encodes a molecule that presents peptide antigens to CD4 1 T lymphocytes. Additional genetic risk variants include CD80 and CD86, which are the binding partners of costimulatory (CD28) and coinhibitory (CTLA4) molecules expressed on T cells. 1, [3] [4] [5] [6] Molecular candidates revealed by GWAS need to be corroborated by functional evidence. Here we pinpoint CTLA4 as an immunological checkpoint in the development of MS.
Patient and Methods
Written informed consent was obtained from the patients according to the Declaration of Helsinki. Immunological and cerebrospinal fluid (CSF) investigations were approved by the local ethics committee.
Histology
Formalin-fixed paraffin-embedded (FFPE) sections of the melanoma and brain biopsy specimen were processed and stained according to standard procedures. Therefore, treatment with the CTLA4 antibody ipilimumab was initiated (4 infusions, 3mg/kg body weight, at 3-weekly intervals), resulting in regression of lymph node metastases. Shortly after the last infusion of ipilimumab, the patient developed severe hypophysitis. Despite treatment with high-dose glucocorticosteroids, hypopituitarism persisted as a known immune-related adverse event of ipilimumab. Course of MS Evidence of radiologically isolated syndrome (RIS) was first observed during the initial tumor staging in August 2010 (see Fig 1 for a synopsis The first clinical episode of MS occurred in March 2012, 4 months after the last infusion of the first course of ipilimumab (see Fig 1) . The patient noted thermhypesthesia of both feet lasting for about 3 weeks. Because MRI evidence of dissemination in time had already been obtained during the preceding RIS phase, a diagnosis of clinically definite MS (CDMS) could be made at the time of the first clinical episode. After the first course of ipilimumab, MRI activity was presumably blunted because the patient was treated with high-dose corticosteroids for hypophysitis; the second course was followed by a massive increase of MRI activity (Figs 1 and 2) . In January 2014, a biopsy of a left-sided periventricular brain lesion was performed to rule out cerebral melanoma metastasis. Histopathological examination showed active MS (T-cell type 
Histological and Immunological Investigations
The primary melanoma contained a dense infiltrate of CD3
1 T cells and CD20 1 B cells at the tumor border ( Fig 3A-F) . The ratio of total CD3 1 to CD8 1 T cells was 3.4:1, and the ratio of CD3 1 T cells to CD20 1 B cells was 3:1 in the melanoma. Quantitative NGS analysis of the TCR repertoire in the melanoma identified numerous strong clonal expansions of both TCR a-and TCR ß-chains (Fig 4) . To rule out brain metastasis, a stereotactic biopsy was performed after the second course of ipilimumab when the patient developed numerous contrast-enhancing cerebral lesions. The brain lesion was classified as pattern 1 (T-cell type) MS (see Fig 3G-O) . and CD8 1 T cells were prominent in both CSF samples but not in the tumor (see Fig 4) .
Discussion
Our clinical, serial MRI, histopathological, and immunological observations indicate that CTLA4 is an immunological checkpoint in the development of MS, that is, transition from subclinical RIS to CDMS as observed here. Although other treatments administered to this patient might have acted as confounders, the close temporal relationship of ipilimumab administration to the documented increases of clinical or MRI activity, coupled with genetic data from the literature, provide a reasonable basis to presume that the observed increases of disease activity were induced by anti-CTLA4 treatment. This interpretation is further supported by 2 additional recent case reports. 11, 12 The first report describes a patient with preexisting multiple sclerosis who had 2 clinical exacerbations and increased MRI activity shortly after initiation of ipilimumab for metastatic melanoma.
11
The second report describes a 76-year-old patient who developed apparently de novo inflammatory CNS demyelination after treatment with ipilimumab for metastatic melanoma in combination with gamma knife stereotactic radiosurgery (SRS). 12 Although SRS can induce inflammatory demyelination in the radiation field, the white matter lesions occurred too early after irradiation and were too widespread to be induced by SRS in this patient. 12 A third report 13 describes a patient whose MS seemed to remain stable after treatment with ipilimumab for melanoma, but the tumor did not respond to ipilimumab, and the patient died due to melanoma progression. The coinhibitory molecule CTLA4 is a structural homologue of the costimulatory molecule CD28. 14, 15 Both molecules are expressed on T cells but they are differently regulated, and their distribution varies among T-cell subsets. CTLA4 is constitutively expressed on regulatory T cells, and is upregulated on conventional T cells after activation. Part of CTLA4 function is achieved by interaction with CD80 and CD86, which are expressed on antigenpresenting cells (APC). Downregulation of CD80 and CD86 by CTLA4 inhibits the antigen-presenting capacity of APC and thereby dampens T-cell activation. 14, 15 "Immune checkpoint therapy" is a promising strategy for treating cancer, 16 and inadvertent stimulation of autoimmune responses is a known risk of checkpoint therapies. 12, 17 However, the precise mechanisms of CTLA4 function are very complex and only incompletely understood. For example, functional studies in conditionally CTLA4-depleted mice showed that CTLA4 deletion in adult mice had opposing impact on different autoimmune models, 18 and that deletion of CTLA4 during adulthood even conferred protection from experimental autoimmune encephalomyelitis (EAE), 18, 19 whereas anti-CTLA4 antibody exacerbated EAE in other models. 20, 21 Our observations indicate that the net effect of ipilimumab in treated human subjects is stimulatory, unleashing preexisting antitumor and anti-CNS autoimmune responses. To investigate the T-cell responses activated by the anti-CTLA4 antibody, we compared the TCR repertoire of tumor-infiltrating T cells present in the primary melanoma, which was resected before ipilimumab therapy was begun, with the TCR repertoire in 2 consecutive CSF samples taken 5 months and 13 months after the second course of ipilimumab therapy (CSF#2 and CSF#3). Using quantitative NGS, we identified distinct clonal expansions of CD4 1 and CD8 1 T cells in the melanoma and CSF. Interestingly, there was considerable overlap between the TCR repertoire in the tumor and the first (CSF#2), but not second (CSF#3) sample (see Fig 4) . Conversely, several expanded T-cell clones were present in both CSF samples, but not in the melanoma. We interpret these findings to indicate that the protective antitumor response and the inadvertent anti-CNS autoimmune response are directed against different antigens, and therefore, composed of distinct TCR clonotypes. We further assume that activated, tumor-specific T cells transiently entered the CNS compartment. It is known that activated T cells can reach the CSF as bystanders, even if they do not recognize CNS antigen. 22, 23 By contrast, the clonally expanded CD4 1 and CD8 1 T cells, which were detectable in both consecutive CSF samples but not in the melanoma, might participate in the autoimmune process of MS in this patient. However, without knowing their detailed phenotype or target specificity, it remains open whether the "CSF-specific" CD4 1 and CD8 1 T-cell expansions act as autoaggressive effectors or protective regulatory cells. In more general terms, our observations support the autoimmune pathogenesis of MS, and specifically, underline the central importance of autoreactive T cells in the pathogenesis of MS. 24, 25 Moreover, they provide functional support for GWAS that implicated T-cell costimulatory and coinhibitory molecular networks as genetic risk factors of MS. 1,3-6 A comprehensive Web-based human genetics resource, ImmunoBase (https://www. immunobase.org), yields strong MS-related hits for CD86 and CD80. CTLA4 and CD28, which map close to each other, do not yield strong signals directly over the genes, but in a presumed regulatory region located between the two genes. As a checkpoint of transition from RIS to CDMS, CTLA4 could be a worthwhile target for immune intervention. In a phase 1 therapeutic trial, the CTLA4 1 TCR a-chains, between the melanoma and CSF#2, but not CSF#3 (A). Furthermore, there are overlaps between CSF#2 and CSF#3 at all levels (TCR a-and ß-chains; CD4
1 and CD8 1 T cells; A and B). The CSF-specific, persistent clonal expansions likely contribute to multiple sclerosis in this patient. Images were generated using CIRCOS software (http:// circos.ca/).
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pathway was targeted with soluble CTLA4-Ig, a CTLA4 agonist. 26 No adverse safety signals were observed in the pilot trial. 26 An NIH-sponsored follow-up phase 2 trial of CTLA4-Ig is currently underway (https://clinicaltrials. gov/ct2/show/NCT01116427?term=CTLA-4+Ig+multiple+sclerosis&rank=1).
